[Aberrant immunophenotypes in acute leukemia in a Buenos Aires' hospital population]

Viviana Novoa1, Neri A Núñez, Orlando G Carballo

  • 1Laboratorio de Inmunología, Unidad de Inmunología e Histocompatibilidad, Hospital de Agudos Dr. Carlos G. Durand, Buenos Aires, Argentina. novoaviviana@yahoo.com.ar

Medicina
|January 22, 2013
PubMed

Insights

Multiparameter flow cytometry (MFC) is crucial for diagnosing acute leukemias by identifying aberrant antigen expression in malignant cells. This method aids in monitoring treatment response by tracking these abnormal cell phenotypes.

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Context:

  • Multiparameter flow cytometry (MFC) is the standard for analyzing acute leukemias.
  • It detects aberrant antigen expression, heterogeneity, and clonality in malignant cells.

Purpose:

  • To analyze membrane antigen expression in acute leukemia blasts.
  • To evaluate the utility of aberrant phenotypes in monitoring treatment response.

Summary:

  • Retrospective analysis of 364 acute leukemia samples using MFC over 7 years.
  • Identified phenotypes for AML (60.2%), B-LLA (28.8%), T-LLA (6.6%), and rare leukemias (4.4%).
  • Aberrant phenotypes were present in 86% of samples, including lineage infidelity, antigen absence/alteration, asynchronous, and ectopic expression.

Impact:

  • MFC effectively identifies aberrant phenotypes in most acute leukemia patients.
  • Tracking these aberrant phenotypes is valuable for monitoring treatment efficacy.

Related Concept Videos